MedPath

The University Of Texas Health Science Center At San Antonio

🇺🇸United States
Ownership
-
Employees
-
Market Cap
-
Website

Clinical Trials

409

Active:9
Completed:264

Trial Phases

6 Phases

Early Phase 1:42
Phase 1:38
Phase 2:50
+3 more phases

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (352 trials with phase data)• Click on a phase to view related trials

Not Applicable
174 (49.4%)
Phase 2
50 (14.2%)
Early Phase 1
42 (11.9%)
Phase 4
39 (11.1%)
Phase 1
38 (10.8%)
Phase 3
9 (2.6%)

SGLT2i, Pioglitazone, and Ketone Production in T1D

Not Applicable
Not yet recruiting
Conditions
Type1diabetes
Interventions
Drug: Pioglitazone 15 MG and 30mg
Other: Placebo
First Posted Date
2025-07-09
Last Posted Date
2025-07-09
Lead Sponsor
The University of Texas Health Science Center at San Antonio
Target Recruit Count
24
Registration Number
NCT07056699
Locations
🇺🇸

Texas Diabetes Institute, San Antonio, Texas, United States

The Effect Of Enamel Matrix Protein On Gingival Tissue Thickness. A Randomized Controlled Trial

Not Applicable
Not yet recruiting
Conditions
Dental Implantation
Missing Teeth
Periodontitis, Adult
Mucositis
First Posted Date
2025-07-08
Last Posted Date
2025-07-08
Lead Sponsor
The University of Texas Health Science Center at San Antonio
Target Recruit Count
32
Registration Number
NCT07053969
Locations
🇺🇸

University of Texas Health Science Center at San Antonio, San Antonio, Texas, United States

Microsurgery and Periodontal Healing

Not Applicable
Not yet recruiting
Conditions
Periodontal Diseases
First Posted Date
2025-07-08
Last Posted Date
2025-07-08
Lead Sponsor
The University of Texas Health Science Center at San Antonio
Target Recruit Count
25
Registration Number
NCT07054008
Locations
🇺🇸

University of Texas Health Science Center at San Antonio, San Antonio, Texas, United States

SGLT2i, Ketoacidosis, Volume Contraction, and Insulinopenia

Not Applicable
Recruiting
Conditions
Type 2 Diabetes
Interventions
First Posted Date
2025-07-08
Last Posted Date
2025-07-11
Lead Sponsor
The University of Texas Health Science Center at San Antonio
Target Recruit Count
29
Registration Number
NCT07053306
Locations
🇺🇸

Texas Diabetes Institute/UH, San Antonio, Texas, United States

SGLT2i, Pioglitazone, and Ketone Production in T2D

Not Applicable
Recruiting
Conditions
Type 2 Diabetes
Interventions
Drug: Empagliflozin 25 MG plus Pioglitazone placebo
Drug: Pioglitazone 15 mg increased to 30 mg after 2 weeks plus Empagliflozin Placebo
Drug: Empagliflozin 25 mg/d plus Pioglitazone (15/30 mg/d)
Drug: Pioglitazone placebo + Empagliflozin placebo
First Posted Date
2025-07-08
Last Posted Date
2025-07-08
Lead Sponsor
The University of Texas Health Science Center at San Antonio
Target Recruit Count
64
Registration Number
NCT07053319
Locations
🇺🇸

Texas Diabetes Institute/UH, San Antonio, Texas, United States

  • Prev
  • 1
  • 2
  • 3
  • 4
  • 5
  • 82
  • Next

News

Breakthrough at UT Health San Antonio: Chemical Endocytic Strategy Could Transform IV Drugs into Oral Treatments

• Researchers at UT Health San Antonio have developed "chemical endocytic medicinal chemistry," a novel approach that could enable large-molecule drugs to be taken orally rather than intravenously. • The discovery leverages CD36 protein receptors on cell surfaces to facilitate cellular uptake of large and water-soluble drugs, potentially overcoming the blood-brain barrier for treating conditions like brain cancer and Alzheimer's disease. • This paradigm shift in drug delivery could revolutionize pharmaceutical development, resurrect previously abandoned drug candidates, and enable more personalized medicine based on patients' varying CD36 expression levels.

Novel Radiotherapeutic Rhenium Obisbemeda Doubles Survival Time in Glioblastoma Patients

A Phase 1 trial led by UT Health San Antonio demonstrated that Rhenium Obisbemeda more than doubled median survival time to 17 months in recurrent glioblastoma patients receiving high doses, compared to the typical 8-month survival.

Novel Senolytic Drug Shows Promise for MASLD and Liver Cancer Treatment

Researchers from UT Health San Antonio and Tulane University have developed a new drug candidate that effectively eliminates senescent "zombie cells" from the liver, showing potential for treating MASLD and liver cancer.

PharmAla to Develop Novel MDMA Dosage Form for Military PTSD Trial at UT Health San Antonio

PharmAla Biotech will supply both 40mg and new 20mg LaNeo MDMA capsules for a Department of Defense-funded PTSD treatment trial targeting active-duty military personnel.

Smartphone App Augments Medication to Reduce Opioid Use, Improve Retention

A recent study reveals that a smartphone app, when used with medication for opioid use disorder (MOUD), significantly reduces opioid use among patients.

PSMD Neuroimaging Marker Shows Promise in Identifying Dementia Risk

A new neuroimaging marker, peak-width of skeletonized mean diffusivity (PSMD), correlates with general cognition and may identify individuals at risk of dementia.

UT Health San Antonio Investigates Gut-Organ Miscommunication in Obesity and Diabetes

Dr. Marzieh Salehi challenges the myth that obesity is solely caused by calorie imbalance, emphasizing the role of gut-organ communication.

UT Health San Antonio Receives $12 Million to Advance Opioid Use Disorder Drug

UT Health San Antonio has been awarded $12 million to develop methocinnamox (MCAM) for opioid use disorder.

Semaglutide Investigated for Diabetes, Obesity in Spinal Cord Injury Patients

A clinical trial is underway to investigate the mechanisms behind diabetes and obesity in individuals with spinal cord injuries.

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.